Onset of Efficacy of Long-Acting Psychostimulants in Pediatric Attention-Deficit/Hyperactivity Disorder

@article{Brams2008OnsetOE,
  title={Onset of Efficacy of Long-Acting Psychostimulants in Pediatric Attention-Deficit/Hyperactivity Disorder},
  author={Matthew N. Brams and Alice R. Mao and Robert L. Doyle},
  journal={Postgraduate Medicine},
  year={2008},
  volume={120},
  pages={69 - 88}
}
Abstract Background: Attention-deficit/hyperactivity disorder (ADHD) adversely impacts the educational achievement, mood and emotion processing, and interpersonal relationships of children and adolescents. Effective treatments include a number extended-release (ER) methylphenidate- (MPH) and amphetamine-based drugs. Some formulations release a comparatively larger bolus after dosing and can result in different onset and duration of efficacy. Objective: Provide an evidence-based description of… 
Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies
TLDR
Emerging head-to-head studies provide important data on the comparative efficacy of the formulations available and are necessary to provide guidance in clinical practice, particularly in the treatment of adults and pre-school children.
Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder
  • J. Najib
  • Psychology, Medicine
    Adolescent health, medicine and therapeutics
  • 2012
TLDR
The pharmacokinetic profile, efficacy, and safety of lisdexamfetamine dimesylate for the treatment of attention-deficit/hyperactivity disorder in children and, more recently, in adolescents are presented.
Erratum to: Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies
TLDR
Emerging head-to-head studies provide important data on the comparative efficacy of the formulations available and are necessary to provide guidance in clinical practice, particularly in the treatment of adults and pre-school children.
Attention-Deficit Hyperactivity Disorder
TLDR
The efficacy and safety of five of the more novel long-acting pharmacological treatments recently approved by the FDA for marketing in the US for paediatric ADHD, along with an α2-adrenoceptor agonist in preparation are considered.
The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD
TLDR
Methylphenidate hydrochloride for extended-release oral suspension (MEROS or QuillivantTM XR) is the first long-acting MPH- ER oral suspension developed to treat attention-deficit/hyperactivity disorder and offers advantages when compared with other MPH-ER preparations for patients who cannot or prefer not to swallow or manipulate capsules or wear a transdermal patch.
Atomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patients
TLDR
Atomoxetine has a trajectory of response that is incremental over a long period of time, with a greater than expected maintenance of response, which has implications for physician atomxetine dosing and efficacy assessment, patient education and outcomes, and for clinical trial design and assessment of comparative efficacy with stimulant medications.
Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications
TLDR
Modifications to routes of administration that may alter PK properties of stimulant-based medication for treating ADHD are reviewed, which are of clinical interest because they may pose safety hazards and affect efficacy.
Lisdexamfetamine Dimesylate
TLDR
The available data, including a large effect size and consistent plasma concentrations throughout the day, suggest that lisdexamfetamine is a useful treatment option for patients with ADHD.
Treatment strategies for ADHD: an evidence-based guide to select optimal treatment
TLDR
An evidence-based appraisal of the literature on ADHD treatment is provided, supplemented by expert opinion on plausibility, and guidance for optimizing initiation of treatment and follow-up of patients in clinical settings is provided.
Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design
TLDR
Stimulant medication use may decrease the risk of injury among children treated for ADHD, although unmeasured time varying confounding may be an alternative explanation.
...
1
2
...

References

SHOWING 1-10 OF 86 REFERENCES
Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
TLDR
Comparisons of efficacy and safety of two long-acting formulations of methylphenidate (MPH) for attention-deficit/hyperactivity disorder (ADHD) in school-age children found both doses are well tolerated.
New options in the pharmacological management of attention-deficit/hyperactivity disorder.
  • M. Olfson
  • Psychology, Medicine
    The American journal of managed care
  • 2004
TLDR
In selecting the appropriate pharmacological regimen, consideration should be given to the child's daily school and after-school schedule, the presence of aggressive symptoms, and the risk of diversion.
Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder.
TLDR
D-MPH-ER is safe and effective and improves classroom attention, deportment, and performance in children with ADHD and maintained significant superiority over placebo from hours 1 through 12.
Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
TLDR
Once-daily d-MPH-ER was more effective than placebo in the treatment of ADHD in children and adolescents.
Efficacy and Safety of Ritalin® LA™, a New, Once Daily, Extended-Release Dosage Form of Methylphenidate, in Children with Attention Deficit Hyperactivity Disorder
TLDR
The results demonstrate that Ritalin® LA™ administered once daily for up to 2 weeks achieved outcomes statistically superior to placebo in children with ADHD.
Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial.
TLDR
The results of this long-term, placebo-controlled study of the central stimulant amphetamine in the treatment of ADHD indicate that there are remaining positive effects of the drug 15 months after starting treatment.
Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
TLDR
A new once-a-day methylphenidate (MPH) formulation, Concerta (methylphenidate HCl) extended-release tablets (OROS MPH), has been developed and showed significantly greater reductions in core ADHD symptoms than did children on placebo.
ADouble-Blind, Placebo-Controlled Withdrawal Trial of Dexmethylphenidate Hydrochloride in Children with Attention Deficit Hyperactivity Disorder
TLDR
This study complements a previous report by studying the effect of placebo-controlled discontinuation and retesting the duration of action of d,l-threo-methylphenidate HCl, the most common treatment of attention deficit hyperactivity disorder (ADHD).
Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
TLDR
Although some children are being diagnosed as having ADHD with insufficient evaluation and in some cases stimulant medication is prescribed when treatment alternatives exist, there is little evidence of widespread overdiagnosis or misdiagnosis of ADHD or ofidespread overprescription of methylphenidate by physicians.
...
1
2
3
4
5
...